Effects of GLP-1 RAs in weight reduction have been well documented, with several GLP-1 RAs (semaglutide and exenatide weekly injections) approved by FDA (Food and Drug Administration) for obesity management. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.